Viking Therapeutics Inc
VKTX31.630USD
+0.930+3.03%
收盘 07/16, 16:00（美东）报价延迟15分钟
3.55B总市值
亏损市盈率 TTM
关于 Viking Therapeutics Inc 公司
Viking Therapeutics, Inc. 是一家临床阶段的生物制药公司，专注于开发治疗代谢和内分泌疾病的疗法。该公司的临床项目包括 VK2809，这是一种口服小分子选择性甲状腺激素受体 β 激动剂，用于治疗脂质和代谢疾病，目前正在进行 II b 期研究，以评估其治疗活检证实的非酒精性脂肪性肝炎 (NASH) 和纤维化的效果。该公司正在开发 VK0214，这也是一种口服组织和受体亚型选择性 TRb 激动剂，用于治疗 X 连锁肾上腺脑白质营养不良 (X-ALD)，这是一种罕见的 X 连锁遗传性神经系统疾病，其特征是大脑和神经细胞周围的保护屏障被破坏。该公司还在开发 VK2735，这是胰高血糖素样肽 1 (GLP-1) 和葡萄糖依赖性胰岛素促泌多肽 (GIP) 受体的双重激动剂，用于治疗各种代谢紊乱。
公司简介
公司代码VKTX
公司名称Viking Therapeutics Inc
上市日期Apr 29, 2015
成立日期2012
CEODr. Brian W. Lian, Ph.D.
员工数量36
证券类型Ordinary Share
年结日Apr 29
公司地址9920 Pacific Heights Blvd, Suite 350
城市SAN DIEGO
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编92121
电话18587044660
网址https://vikingtherapeutics.com/
公司代码VKTX
上市日期Apr 29, 2015
成立日期2012
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Lawson Macartney, Ph.D.
Dr. Lawson Macartney, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
47.97K
--
Mr. Greg Zante, CPA
Mr. Greg Zante, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Marianne Mancini
Ms. Marianne Mancini
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Matthew William (Matt) Foehr
Mr. Matthew William (Matt) Foehr
Independent Director
Independent Director
--
--
Dr. S. Kathy Rouan, Ph.D.
Dr. S. Kathy Rouan, Ph.D.
Independent Director
Independent Director
--
--
Mr. Charles A. (Charlie) Rowland, Jr.
Mr. Charles A. (Charlie) Rowland, Jr.
Independent Director
Independent Director
--
--
Mr. J. Matthew Singleton, CPA
Mr. J. Matthew Singleton, CPA
Independent Director
Independent Director
--
--
Dr. Brian W. Lian, Ph.D.
Dr. Brian W. Lian, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
名称
名称/职务
职务
持股
持股变动
Dr. Lawson Macartney, Ph.D.
Dr. Lawson Macartney, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
47.97K
--
Mr. Greg Zante, CPA
Mr. Greg Zante, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Marianne Mancini
Ms. Marianne Mancini
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Matthew William (Matt) Foehr
Mr. Matthew William (Matt) Foehr
Independent Director
Independent Director
--
--
Dr. S. Kathy Rouan, Ph.D.
Dr. S. Kathy Rouan, Ph.D.
Independent Director
Independent Director
--
--
Mr. Charles A. (Charlie) Rowland, Jr.
Mr. Charles A. (Charlie) Rowland, Jr.
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 5月16日 周五
更新时间: 5月16日 周五
持股股东
股东类型
持股股东
持股股东
占比
Fidelity Management & Research Company LLC
9.11%
The Vanguard Group, Inc.
9.03%
BlackRock Institutional Trust Company, N.A.
4.34%
State Street Global Advisors (US)
3.61%
JP Morgan Asset Management
2.41%
Other
71.51%
持股股东
持股股东
占比
Fidelity Management & Research Company LLC
9.11%
The Vanguard Group, Inc.
9.03%
BlackRock Institutional Trust Company, N.A.
4.34%
State Street Global Advisors (US)
3.61%
JP Morgan Asset Management
2.41%
Other
71.51%
股东类型
持股股东
占比
Investment Advisor
29.46%
Investment Advisor/Hedge Fund
24.98%
Hedge Fund
8.22%
Research Firm
4.13%
Individual Investor
2.15%
Sovereign Wealth Fund
1.14%
Bank and Trust
0.77%
Pension Fund
0.74%
Private Equity
0.45%
Other
27.95%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
859
81.00M
72.12%
-18.38M
2025Q1
881
81.93M
72.95%
-19.61M
2024Q4
837
90.73M
82.19%
-16.87M
2024Q3
781
90.59M
82.61%
-15.25M
2024Q2
701
89.78M
82.34%
-10.20M
2024Q1
634
89.55M
82.55%
-7.02M
2023Q4
464
85.12M
85.96%
-16.14M
2023Q3
442
85.70M
86.63%
-10.01M
2023Q2
426
82.52M
83.46%
-982.32K
2023Q1
408
74.30M
93.67%
+22.84M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Fidelity Management & Research Company LLC
10.23M
9.11%
-6.28M
-38.05%
Mar 31, 2025
The Vanguard Group, Inc.
10.14M
9.03%
-8.18K
-0.08%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
4.87M
4.34%
+31.60K
+0.65%
Mar 31, 2025
State Street Global Advisors (US)
4.06M
3.61%
-870.07K
-17.66%
Mar 31, 2025
JP Morgan Asset Management
2.70M
2.41%
+664.27K
+32.59%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.98M
1.77%
+103.68K
+5.51%
Mar 31, 2025
Lian (Brian)
1.92M
1.71%
-446.09K
-18.85%
Mar 15, 2025
Pictet Asset Management Ltd.
1.92M
1.71%
+684.34K
+55.32%
Mar 31, 2025
Morgan Stanley & Co. LLC
1.79M
1.6%
+412.62K
+29.89%
Mar 31, 2025
Susquehanna International Group, LLP
1.68M
1.49%
+643.39K
+62.26%
Mar 31, 2025
查看更多
持股ETF
更新时间: 7月6日 周日
更新时间: 7月6日 周日
机构名称
占比
Roundhill GLP-1 & Weight Loss ETF
4.14%
Formidable ETF
1.56%
Amplify Weight Loss Drug & Treatment ETF
1.33%
SPDR S&P Biotech ETF
1.09%
Tema Heart & Health ETF
1%
Virtus LifeSci Biotech Clinical Trials ETF
0.87%
Direxion Daily S&P Biotech Bull 3X Shares
0.72%
Nuveen ESG Small-Cap ETF
0.33%
Amplify AI Powered Equity ETF
0.26%
Inspire Small/Mid Cap ESG ETF
0.24%
查看更多
Roundhill GLP-1 & Weight Loss ETF
占比4.14%
Formidable ETF
占比1.56%
Amplify Weight Loss Drug & Treatment ETF
占比1.33%
SPDR S&P Biotech ETF
占比1.09%
Tema Heart & Health ETF
占比1%
Virtus LifeSci Biotech Clinical Trials ETF
占比0.87%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.72%
Nuveen ESG Small-Cap ETF
占比0.33%
Amplify AI Powered Equity ETF
占比0.26%
Inspire Small/Mid Cap ESG ETF
占比0.24%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
